Polymyositis News and Research

RSS
Polymyositis is a fairly uncommon condition that leads to increasing weakness of the skeletal muscles (those muscles involved in movement) and it can affect the body bilaterally (on both sides).

Further Reading

Novel member of a class of anti-diabetes drugs could help treat muscle wasting disease

Novel member of a class of anti-diabetes drugs could help treat muscle wasting disease

Targeting necroptosis using a necroptosis inhibitor lessens myositis-induced muscle weakness

Targeting necroptosis using a necroptosis inhibitor lessens myositis-induced muscle weakness

FDA grants seven years of marketing exclusivity for Octapharma’s Octagam 10%

FDA grants seven years of marketing exclusivity for Octapharma’s Octagam 10%

Breakthrough SARS-CoV-2 infections in patients with systemic rheumatic diseases

Breakthrough SARS-CoV-2 infections in patients with systemic rheumatic diseases

Lupus patients receiving prophylactic therapy are at high risk for adverse reactions

Lupus patients receiving prophylactic therapy are at high risk for adverse reactions

Patients and families gather to gain more awareness, knowledge about myositis

Patients and families gather to gain more awareness, knowledge about myositis

New classification criteria offers faster, more accurate path to diagnosing myositis diseases

New classification criteria offers faster, more accurate path to diagnosing myositis diseases

Endurance training can be helpful in dealing with muscle inflammation

Endurance training can be helpful in dealing with muscle inflammation

Exoskeleton device helps man with disabling condition to complete 10K race

Exoskeleton device helps man with disabling condition to complete 10K race

Statin medications can cause necrotizing myopathy in some patients

Statin medications can cause necrotizing myopathy in some patients

Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Anti-TNF therapy offers new hope to JDM patients

Anti-TNF therapy offers new hope to JDM patients

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Clinical study data on Mallinckrodt's H.P. Acthar Gel to be presented at ACR 2015

Former all-American wrestler speaks about his personal battle with chronic muscle disease

Former all-American wrestler speaks about his personal battle with chronic muscle disease

Researchers identify link between autoimmune diseases, medications and Long QT syndrome

Researchers identify link between autoimmune diseases, medications and Long QT syndrome

Idera collaborates with TMA to advance new potential treatment approach for myositis

Idera collaborates with TMA to advance new potential treatment approach for myositis

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Idera Pharmaceuticals reports positive top-line results from Phase 2 trial of IMO-8400

Idera Pharmaceuticals reports positive top-line results from Phase 2 trial of IMO-8400

Questcor acquires rights to develop Synacthen and Synacthen Depot in US

Questcor acquires rights to develop Synacthen and Synacthen Depot in US

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.